LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Search

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

35.74 2.06

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.02

Max

36.71

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.9M

-66M

EPS

-0.84

Angestellte

316

EBITDA

-3.8M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+57.05% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.7M

2.9B

Vorheriger Eröffnungskurs

33.68

Vorheriger Schlusskurs

35.74

Nachrichtenstimmung

By Acuity

67%

33%

333 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2025, 23:48 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11. Mai 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11. Mai 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11. Mai 2025, 23:38 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Aristocrat Has Significant Firepower for M&A -- Market Talk

11. Mai 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11. Mai 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11. Mai 2025, 23:33 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11. Mai 2025, 23:32 UTC

Top News

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11. Mai 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11. Mai 2025, 22:33 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11. Mai 2025, 20:19 UTC

Top News

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11. Mai 2025, 16:00 UTC

Top News

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11. Mai 2025, 11:00 UTC

Top News

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11. Mai 2025, 08:00 UTC

Top News

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11. Mai 2025, 01:00 UTC

Top News

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11. Mai 2025, 01:00 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10. Mai 2025, 21:54 UTC

Top News

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10. Mai 2025, 17:12 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10. Mai 2025, 15:41 UTC

Top News

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10. Mai 2025, 12:00 UTC

Top News

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10. Mai 2025, 09:30 UTC

Top News

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10. Mai 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10. Mai 2025, 03:52 UTC

Top News

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9. Mai 2025, 23:51 UTC

Akquisitionen, Fusionen, Übernahmen

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9. Mai 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9. Mai 2025, 21:37 UTC

Top News

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9. Mai 2025, 21:10 UTC

Top News

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9. Mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Mai 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9. Mai 2025, 20:42 UTC

Top News

Stocks Get a Break From Trade Chaos -- WSJ

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

57.05% Vorteil

12-Monats-Prognose

Durchschnitt 55 USD  57.05%

Hoch 65 USD

Tief 42 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

14

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

333 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.